title: [Management of adverse effects related to human immunoglobulin therapy: Recommendations for clinical practice].
abstract: Both intravenous and subcutaneous immunoglobulins are therapeutic modalities approved in various conditions, including primary and secondary immune deficiencies and autoimmune disorders. To date, immunoglobulins have more often been considered as a safe medication, with minor adverse effects such as hypertension, fever and chills, nausea, myalgia or headache. However, with the wider use of immunoglobulins in the treatment of autoimmune diseases, severe side effects have also been reported to occur in immunoglobulin-treated patients, especially anaphylaxis, aseptic meningitis, acute renal impairment, thrombotic events as well as haematological manifestations. This paper reviews all the potential adverse events related to immunoglobulin therapy and establishes a comprehensive guideline for the management of these events.
authors.affiliation: Département de médecine interne, CHU de Rouen, 1, rue de Germont, 76031 Rouen, France. Electronic address: isabelle.marie@chu-rouen.fr.
authors.forename: I
authors.initials: I
authors.lastname: Marie
authors.affiliation: Service de médecine interne, groupe hospitalier Pitié-Salpêtrière, 75013 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Chérin
authors.affiliation: Service d'hématologie, hospices civils de Lyon, hôpital Lyon-Sud, 69310 Pierre-Bénite, France.
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.affiliation: Service de pharmacie, hôpitaux civils de Colmar, 68000 Colmar, France.
authors.forename: E
authors.initials: E
authors.lastname: Pelus
authors.affiliation: Département de néphrologie, d'immunologie clinique, de transplantation, CHU de Nantes, 44093 Nantes, France.
authors.forename: J
authors.initials: J
authors.lastname: Dantal
authors.affiliation: Octapharma, 92100 Boulogne-Billancourt, France.
authors.forename: J-C
authors.initials: JC
authors.lastname: Crave
authors.affiliation: Octapharma, 92100 Boulogne-Billancourt, France.
authors.forename: J-C
authors.initials: JC
authors.lastname: Delain
authors.affiliation: Service de médecine interne, CHU Bordeaux, 33604 Pessac, France.
authors.forename: J-F
authors.initials: JF
authors.lastname: Viallard
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced; D064420:Drug-Related Side Effects and Adverse Reactions / Q000276:immunology / Q000628:therapy*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007049:Iatrogenic Disease / Q000517:prevention & control; D007116:Immunization, Passive / Q000009:adverse effects* / Q000379:methods; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D017410:Practice Guidelines as Topic; D013927:Thrombosis / Q000139:chemically induced
chemical_list: D016756:Immunoglobulins, Intravenous
keywords: Acute renal failure; Complications hématologiques; Hematological complications; Immunoglobulines intraveineuses; Immunoglobulines sous-cutanées; Insuffisance rénale aiguë; Intravenous immunoglobulins; Subcutaneous immunoglobulins; Thromboses; Thrombotic events